Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Factbox: AstraZeneca's potential coronavirus vaccine

share with twitter share with LinkedIn share with facebook
08/06/2020 | 09:45am EDT

AstraZeneca signed its first COVID-19 vaccine supply deal with a Chinese company, Kangtai Bio, on Thursday, opening up distribution to one of the world's most populous countries.

Drugmakers are racing to combat the pandemic that has now killed about 800,000 people.

There are no approved vaccines for COVID-19, but AstraZeneca's shot is widely seen as one of the leading candidates.

The company has been granted protection from future product liability claims related to the vaccine by most of the countries with which it has so far struck supply agreements, a senior executive told Reuters.

Below are the main details of AstraZeneca's coronavirus vaccine hopeful and its supply and production deals.


*The shot, called AZD1222 or ChAdOx1 nCoV-19, is a recombinant viral vector vaccine developed by Oxford University.

*It was licensed to AstraZeneca in April.

*The vaccine candidate uses a weakened version of a common-cold virus that encodes instructions for making proteins from the novel coronavirus to build immunity.


*The shot is likely to provide protection for about a year, and the company is leaning towards a two-dose strategy for the potential vaccine.


*AstraZeneca says it will be able to manufacture the vaccine at a few dollars per dose.

*According to Italy's health ministry, an AZD1222 shot would cost about 2.5 euros ($2.8) per dose in Europe.

* AstraZeneca has said it does not expect to profit from the vaccine candidate during the pandemic.

*Costs in other regions have not been disclosed.


*AstraZeneca's CEO said good data has come in so far on the shot, after early-stage clinical trials showed it was safe and produced an immune response.

*Late-stage trials are currently underway in Britain, Brazil and South Africa, and are due to start in the United States in the third quarter.

*Talks are ongoing with Mexico, and reports have said the Indian regulator has also given a nod for mid-to-late-stage trials.


*The vaccine could be rolled out by year-end, but there is no certainty of that, its lead developer said in July.

*Data from late-stage studies is expected by August to September.

*Delivery of the first doses is expected between September and October.

*Experts predict a safe and effective vaccine could take 12-18 months to develop.


*More than 2.1 billion


*With U.S. backing, AstraZeneca has tied up with IQVIA to speed up trials. Even before conclusive evidence of the vaccine's success or failure, AstraZeneca has signed other deals to produce and supply the shot.

AstraZeneca is also in talks with Japan and Spain.

(Reporting by Pushkala Aripaka in Bengaluru; Additional reporting by Tanishaa Nadkar; Editing by Jason Neely, Nick Macfie, Sherry Jacob-Phillips and Jan Harvey)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.69% 8077 Delayed Quote.4.42%
DOW JONES AFRICA TITANS 50 INDEX -0.66% 479.95 Delayed Quote.-9.41%
DOW JONES SOUTH AFRICA(ZAR) -0.61% 1684.08 Delayed Quote.-6.09%
EURO / BRAZILIAN REAL (EUR/BRL) -0.26% 6.6437 Delayed Quote.47.90%
IQVIA HOLDINGS INC. -3.72% 161.415 Delayed Quote.8.39%
S&P AFRICA 40 INDEX -1.34% 158.61 Delayed Quote.-6.80%
UNITED PARCEL SERVICE, INC. -2.70% 167.5312 Delayed Quote.46.85%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
02:36pStocks slide on surging COVID-19 cases, stimulus doubts; dollar rises
01:28pTravel, energy stocks drag UK shares lower, weighed by coronavirus fears
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
01:13pSAP drags down German shares, COVID-19 worries weigh on broader Europe
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
10:33aWALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
09:44aREVOLUTION MEDICINES : Reports Progress and Expansion of Combination Strategy wi..
09:44aINNATE PHARMA : SA - First patient dosed in monalizumab Phase 3 clinical trial t..
09:22aStocks dip on surging virus cases, stimulus doubts
09:16aNEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (USD)
Sales 2020 26 703 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 178 M - -
P/E ratio 2020 47,1x
Yield 2020 2,72%
Capitalization 138 B 138 B -
EV / Sales 2020 5,67x
EV / Sales 2021 4,94x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,27 $
Last Close Price 103,58 $
Spread / Highest target 50,1%
Spread / Average Target 14,2%
Spread / Lowest Target -36,3%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999